Position Papers

Position Papers on Pending Legislation - Click on link to view PDF

A1832 - Pain Medication

January 3, 2013: Restricts health insurers from limiting access to pain medication.

NAHU Summary of Presidential Candidates on Healthcare

October 26, 2012 - NAHU has compiled an overview of the Presidential Candidates on the Healthcare Issue.

State Regulation of Navigators

On March 23, 2010, President Obama signed H.R. 3590, the Patient Protection and Affordable Care Act (PPACA), and on March 30, 2010, H.R. 4872, the Health Care and Education Affordability Reconciliation Act of 2010, a companion package of "fixes" to H.R. 3590, was signed into law. Taken together, the two measures make the most profound changes to our country's private-market health care system in 50 years.


May 10, 2012: Out of network providers must make a good faith effort to collect member liability. Network providers may not ask payment in excess of co-pay, deductible and coinsurance. Medical services provided by a non-network provider at a network facility must be paid at the carrier contracted rate. Applies to fully insured and self-funded. Applies to hospital, medical and Medicare supplement.


January 10, 2012: Requires insurers to cover comprehensive ultrasound breast screening if a mammogram demonstrates dense breast tissue and requires mammogram reports to contain information on breast density.

December 19, 2011: Exempts individuals with certain types of military service from certain fees and continuing education and professional competency requirements.

December 12, 2011: Requires hearing and approval of premium changes for individual and small employer health benefits.

S-3112 / A4299
November 28, 2011: Requires hearing and approval of premium changes for individual and small employer health benefits plans; and expands jurisdiction of Division of Rate Counsel

November 17, 2011: Requires fully insured individual and group health insurance plans including the State Health Benefits and State Employees Plans to cover oral cancer drugs and related support drugs on the same basis as intravenous cancer medications and related support drugs.